国际肿瘤学杂志

国际肿瘤学杂志 ›› 2015, Vol. 42 ›› Issue (8): 641-.doi: 10.3760/cma.j.issn.1673-422X.2015.09.001

• 论著 • 上一篇    下一篇

康莱特注射液联合低功率超声空化治疗恶性肿瘤的临床观察

沈水杰, 章永红   

  1. 南京中医药大学南通附属医院肿瘤
  • 出版日期:2015-09-08 发布日期:2015-08-12

Clinical observation for the treatment of malignant tumor by Kanglaite injection combined low power ultrasonic cavitation

SHEN  Shui-Jie, ZHANG  Yong-Hong   

  1. Department of Oncology， Nantong Affiliated Hospital， Nanjing University of Traditional Chinese Medicine
  • Online:2015-09-08 Published:2015-08-12

PDF

1051

被引次数

2

摘要： 目的探讨康莱特注射液联合低功率超声辐射微泡试剂致肿瘤血管栓塞疗法（空化）的临床疗效及安全性。方法将38例腹腔恶性肿瘤患者采用随机数字表法分为2组：治疗组（康莱特联合超声空化21例），对照组（康莱特治疗17例）。静脉滴注康莱特注射液200 ml/d，共21 d。超声空化治疗每周治疗5 d，1次/d，共3周。测量患者治疗前后瘤体大小，同时进行Karnofsky评分，检测癌痛程度分级和相关血生化指标。结果治疗组无完全缓解患者，部分缓解4例，疾病稳定10例，临床获益率为66.7%（14/21）；对照组无完全缓解患者，部分缓解1例，疾病稳定3例，临床获益率为23.5%（4/17）。治疗组临床获益率（66.7%∶23.5%）、癌痛改善（76.2%∶41.2%）、Karnofsky评分［（66.67±5.77）∶（82.86±6.44）；（64.12±5.07）∶（69.41±6.59）］、1年生存率（57.1%∶23.5%）均优于对照组，差异有统计学意义（χ2=7.012，P=0.008；χ2=4.821，P=0.028；t=4.575，P<0.001；χ2=4.354，P=0.037）。结论康莱特注射液联合低功率超声空化的临床有效率较高，不良反应可耐受，能够显著改善患者的生命质量。

关键词: 肿瘤/ 超声疗法/ 栓塞, 治疗性/ 康莱特注射液

Abstract: ObjectiveTo investigate the clinical curative effect and security of Kanglaite injection in combination with low power ultrasound microbubble agents (cavitation) in the treatment of vascular embolization therapy. MethodsThirtyeight patients with abdominal malignant tumor, in accordance with the random number table, were divided into two groups: treatment group (Kanglaite combined with ultrasonic cavitation, 21 cases) and control group (Kanglaite, 17 cases). Intravenous drip with Kanglaite injection for 21 days, 200 ml per day. Ultrasonic cavitation therapy treatment for three weeks, 5 days a week and once a day. Tumors size, Karnofsky score, grade of the degree of pain and blood biochemical indicator detection were measyred before and after treatment. ResultsThere was no complete remission, 4 cases with partial remission, 10 cases with stable disease in the treatment group, and the clinical benefit rate was 66.7% (14/21). There was no complete remission, 1 case with partial remission, 3 cases with stable diseasein in control group, and the clinical benefit rate was 23.5% (4/17). The treatment group was better than control group in clinical benefit rate （66.7%∶23.5%）， pain improvement （76.2%∶41.2%）， Karnofsky score［（66.67±5.77）∶（82.86±6.44）； （64.12±5.07）∶（69.41±6.59）］, and one year survival rate （57.1%∶23.5%）(χ2=7.012， P=0.008； χ2=4.821， P=0.028； t=4.575， P<0.001； χ2=4.354， P=0.037). ConclusionKanglaite injection in combination with cavitation shows higher clinical efficient, tolerated adverse recations, and significant improvement of quality of life.